


Background

- ‡ Porustobart (HBM4003) is a next generation anti-LA4 fully human heavy chain only monoclonal antibody (HCAb) engineered to deplete Treg cells by enhanced antibody dependent cellular cytotoxicity (ADCC) activity.
- ‡ Toripalimab is a humanized immunoglobulin G4 monoclonal antibody against PD-1, which is approved for the treatment of melanoma in China.
- ‡ HBM4003 and toripalimab have complementary mechanisms to harness antitumor immune response.
- ‡ Here we reported updated results of a phase I study that evaluated HBM4003 plus toripalimab in advanced melanoma.

Design and Method

- ‡ This study includes two parts. In the dose escalation part, patients with solid tumors received HBM4003 at 3 dose levels (0.03 mg/kg [n=1], 0.1 mg/kg [n=3], and 0.3 mg/kg [n=10]) plus toripalimab 240 mg every three weeks (Q3W). In the dose expansion part, patients with advanced melanoma (n=26) received the recommended phase 2 dose (RP2D) of HBM4003 0.3 mg/kg plus toripalimab 240 mg Q3W.



Baseline Demographics

- ‡ As of 31 Aug 2022, a total of 40 patients had been dosed.
- ‡ A total of 36 patients were treated with RP2D in Part 1 (10 patients) and Part 2 (-12 303>> BDC q 0.000014305 0 960 540 re W* n BT /F8 6 Tf 1 0 0 1 429.22 353.26 Tm 0 g 0 G [(0)-3((-)8(0)-3(0)-5(0))] TJ ET Q EMC /P <</MCID 304>> BDC q 0.000014305 0 960 540 re W* n BT /F8 6 Tf 1 0 0 1 266.06 343.99

Pharmacokinetics